IP Library Granted Patent US 11,268,119
Granted Patent B2
US 11,268,119 · App. 15/519,731 · Granted Mar 8, 2022

Copper supplementation for control of glycosylation in mammalian cell culture process

Inventors: Fernie Mitchelson (Morrisville, NC); Erik Heller Hughes (Raleigh, NC); Jessica Mondia (Medford, MA); Robin Parish Hyde-Deruyscher (Chapel Hill, NC)
Assignee: Biogen MA Inc.
C12P21/005C07K16/2839C12N5/0018C07K2317/14C07K2317/40C07K2317/41C12N2500/10C12N2500/20C12N2511/00C12N2513/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,268,119
App. No.
15/519,731
Granted
Mar 8, 2022
Kind
B2
Abstract

The present invention pertains to a cell culture medium comprising copper as a media supplement, which was shown to control recombinant protein glycosylation and methods of using thereof. The present invention further pertains to a method of controlling or manipulating glycosylation of a recombinant protein of interest in a large scale cell culture.

Claims (12)

1. A method for achieving a predetermined galactosylation profile of an anti-α4-integrin antibody comprising:

culturing host cells producing the anti-α4-integrin antibody in a cell culture comprising an amount of copper within a target copper concentration range, wherein the target copper concentration range in the cell culture is between 200 nM and 500 nM, wherein the target copper concentration is achieved by supplementing the cell culture with a yeast hydrolysate comprising copper.

2. The method of claim 1 , comprising supplementing the cell culture with the yeast hydrolysate comprising copper if the copper concentration in the cell culture is below the target copper concentration range.

3. The method of claim 1 , wherein the target copper concentration is maintained through a feedback loop.

4. The method of claim 1 , wherein the copper concentration is constantly monitored and maintained within the target copper concentration range.

5. The method of claim 1 , wherein the target copper concentration is achieved with a single dose of the yeast hydrolysate comprising copper.

6. The method of claim 1 , wherein the anti-α4-integrin antibody is produced by a eukaryotic host cell.

7. The method of claim 6 , wherein the eukaryotic host cell is a mammalian host cell.

8. The method of claim 1 , wherein the copper concentration alters the levels of the isoform variants of the anti-α4-integrin antibody.

9. The method of claim 1 , wherein the anti-α4-integrin antibody is natalizumab.

10. The method of claim 1 , wherein the yeast hydrolysate used to supplement the cell culture comprises copper (II) sulfate.

11. The method of claim 1 , wherein the target copper concentration range in the cell culture is transitioned to between 200 nM and 500 nM after an initial culture comprising a target copper concentration of between 20 nM and 50 nM.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2018
From: MITCHELSON, FERNIE; HUGHES, ERIK HELLER; MONDIA, JESSICA; HYDE-DERUYSCHER, ROBIN PARISH
To: BIOGEN MA INC.
Reel/Frame 044906/0800 →
Cited By (2)
US 12,606,627 US 12,703,749